CRDL

Cardiol Therapeutics
CRDL

$2.35
2.69%
 

About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Employees: 17

0
Funds holding %
of 6,656 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

2,720% more call options, than puts

Call options by funds: $23.7K | Put options by funds: $840

4% more capital invested

Capital invested by funds: $5.77M [Q3] → $6.02M (+$242K) [Q4]

0.76% more ownership

Funds ownership: 9.86% [Q3] → 10.62% (+0.76%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

9% less funds holding

Funds holding: 34 [Q3] → 31 (-3) [Q4]

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
240%
upside
Avg. target
$8.67
269%
upside
High target
$9
283%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Edward Nash
240%upside
$8
Buy
Maintained
23 May 2024
HC Wainwright & Co.
Vernon Bernardino
283%upside
$9
Buy
Reiterated
14 May 2024
HC Wainwright & Co.
Vernon Bernardino
283%upside
$9
Buy
Initiated
22 Apr 2024

Financial journalist opinion

Based on 4 articles about CRDL published over the past 30 days

Neutral
Newsfile Corp
1 month ago
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024 CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditis Exceeded 50% enrollment in the Phase II ARCHER trial evaluating CardiolRx™in patients with acute myocarditis; study expected to reach full enrollment during Q3 2024 Data presented at the HFSA Annual Scientific Sessions 2023 demonstrated that the API in Cardiol's novelCRD-38 formulation attenuates harmful fat distribution and key markers of cardiac inflammation andremodelling in a model of heart failure with preserved ejection fraction Cash and cash equivalents of $34.9 million as of December 31, 2023,which funds operations into 2026 Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announces its year-end 2023 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2023. Both are available under the Company's profile on SEDAR+ at sedarplus.ca and on the Company's website at cardiolrx.com.
Cardiol Therapeutics Announces Year-End 2023 Update on Operations